这的确对于LAM病人是一个非常好的消息，雷帕霉素临床试验（MILES Trial）终于被获准通过，这对于LAM的治疗又是一个具有里程碑意义的大事件，目前试验向更多的LAM病人开放，可以自由加入，但是您的FEV1也就是肺功能检测中第一秒的呼出量是在70%或以下的才会被获准参加，接下来关于临床试验的细节问题会陆续为大家解读。
主题: Great news!
日期: Fri, 7 Jul 2006 15:00:12 -0400
发件人: "Sue Byrnes" < sbyrnes@thelamfoundation.org>
Hi Everyone,
This email is being sent blind copy to protect your confidentiality.
I am thrilled to announce that the MILES Trial has been fully approved!!! What a thrill after all of the challenges ! We have been cleared of all regulatory issues and checking processes, so we are free to enroll. The principal investigators of the trial will test the systems with a few patients first to make sure that everything is in place and working well. I f you are interested in participating and have not registered on the site given to you in my last mailing – be sure to do so because we are ready to roll - finally!
I do know that your FEV1 score must be 70% or below to participate in this trial , but I don't have any of the other particulars or details about the sites, etc. P lease don't bombard me with lots of questions that I can' t answer – this email is going to over 600 people ! We will send a postcard soon to all LAM patients, but if you know of a LAM patient who does not have email, please share the good news. Thanks to all of you for helping us to get here - this is a day of celebration!
Sue
The LAM Foundation
10105 Beacon Hills Drive, Cincinnati, OH 45241
(513) 777-6889 Fax (513) 777-4109
|
打印本页
关闭窗口